Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab maintenance dose optimization in eosinophilic esophagitis
2026-526348-11-01Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of dupilumab in eosinophilic esophagitis (EoE) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Maintenance of complete remission at Week 52. Planned start Sep 2026; status: authorised.
02
Drugs
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2026-526348-11-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526348-11-01.